Peripheral Artery Disease

Harnessing Genetic Insights: Polygenic Risk Score Enhances Prediction of Peripheral Artery Disease and Limb Events

By MedXY 09/06/2026

A validated polygenic risk score (PRS) independently predicts peripheral artery disease (PAD) and major adverse limb events (MALE) in patients with cardiometabolic disease, adding modest but significant predictive value beyond traditional clinical risk factors.

Cardiology Internal Medicine news

Bempedoic Acid Significantly Reduces Limb and Cardiovascular Events in Statin-Intolerant Patients with Peripheral Artery Disease: Insights from the CLEAR Outcomes Trial

By MedXY 08/22/2026

Bempedoic acid reduces the risk of major adverse limb and cardiovascular events in statin-intolerant patients with peripheral artery disease, illustrating its potential to enhance vascular risk management.

Cardiology General Surgery news

Declining Use But Persistent Readmissions: A National Analysis of Open Lower Extremity Revascularization Outcomes

By MedXY 08/19/2026

This national study identifies key factors linked to 30-day nonelective readmissions after open lower extremity revascularization, highlighting stable readmission rates despite reduced procedure volume and the need for standardized discharge strategies.

Cardiology news

Peripheral Artery Disease: Emerging Advances in Medical Therapy to Reduce Cardiovascular and Limb Risks

By MedXY 07/18/2026

This article reviews recent advances in the medical management of peripheral artery disease, emphasizing comprehensive risk factor control, novel pharmacotherapies, and individualized approaches to improve cardiovascular and limb outcomes in affected patients.

Cardiology Internal Medicine news

Long-Term SAFE-PAD Data Reassure on Mortality After Paclitaxel-Coated Femoropopliteal Interventions

By MedXY 05/06/2026

In Medicare patients undergoing femoropopliteal revascularization, drug-coated devices were not associated with higher long-term mortality, supporting the safety of paclitaxel-coated technology after years of regulatory concern.

Cardiology Clinical Updates news

Intramuscular Adipose Tissue Accumulation as a Key Determinant of Muscle Dysfunction in Peripheral Artery Disease

By MedXY 03/10/2026

This review synthesizes evidence that intramuscular adipose tissue (IMAT) accumulation, driven by fibroadipogenic progenitors, is a primary driver of limb dysfunction in PAD/CLTI, identifying IMAT as a novel therapeutic target.

Cardiology news

VOYAGER-PAD Insight: Prior Revascularization History Mandates More Aggressive Antithrombotic Therapy

By MedXY 02/27/2026

A VOYAGER-PAD sub-analysis reveals that patients with prior limb revascularization are at significantly higher risk for adverse events but derive a greater relative benefit from low-dose rivaroxaban plus aspirin.

Cardiology Internal Medicine news

Metformin Fails to Improve Walking Performance in Peripheral Artery Disease: Results of the PERMET Randomized Trial

By MedXY 02/23/2026

The PERMET randomized clinical trial found that metformin did not improve the 6-minute walk distance or secondary walking outcomes in patients with peripheral artery disease without diabetes, suggesting no benefit for functional impairment in this population.

Cardiology Diabetes & Endocrinology news

Semaglutide Delivers Consistent Functional Gains in Peripheral Artery Disease Regardless of Sex: Evidence from the STRIDE Trial

By MedXY 01/17/2026

A post hoc analysis of the STRIDE trial reveals that once-weekly semaglutide 1.0 mg significantly improves walking distance and quality of life in both men and women with type 2 diabetes and peripheral artery disease, despite notable differences in baseline clinical profiles.

Cardiology Internal Medicine news

Safety Profile Favors Apixaban Over Rivaroxaban in High-Risk Patients with Atrial Fibrillation and Peripheral Artery Disease

By MedXY 01/05/2026

A large-scale cohort study reveals that while rivaroxaban and apixaban offer similar protection against limb events and stroke in patients with AF and PAD, rivaroxaban is associated with a 55% higher risk of major bleeding, suggesting apixaban as a safer alternative.

Cardiology news

Polygenic Risk Score Predicts Peripheral Artery Disease and Major Adverse Limb Events but Offers Modest Incremental Discrimination

By MedXY 12/02/2025

In pooled analyses of six TIMI trials (n=68,816), a validated PAD polygenic risk score was independently associated with prevalent PAD (OR per 1-SD 1.15) and incident major adverse limb events (HR per 1-SD 1.30), but added only modest improvement in risk discrimination beyond clinical factors.

Cardiology Internal Medicine news

Metformin Does Not Improve Walking Distance in Peripheral Artery Disease: Results from the PERMET Randomized Trial

By MedXY 11/08/2025

The PERMET randomized, double-blind trial found that 6 months of metformin did not improve 6-minute walk distance or other functional endpoints in people with lower extremity peripheral artery disease (PAD) without diabetes.

Cardiology news Specialties

Paclitaxel-coated vs Uncoated Devices in Infrainguinal Revascularisation: Insights from the SWEDEPAD 2 Trial

By MedXY 09/17/2025

The SWEDEPAD 2 trial reveals that paclitaxel-coated devices do not improve quality of life at 1 year and raise concerns about increased 5-year mortality in patients with intermittent claudication undergoing lower limb revascularisation.

Clinical Updates Family Medicine & Nutrition news

Timing Matters: Determining the Optimal Duration of Supervised Exercise for Meaningful Improvements in Peripheral Artery Disease

By MedXY 09/08/2025

A supervised treadmill exercise program lasting over 6 weeks is essential to achieve significant walking improvements in peripheral artery disease, with peak patient-reported benefits observed at 12 weeks but diminishing by 26 weeks.

Clinical Updates Diabetes & Endocrinology news Specialties

Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial

By MedXY 09/07/2025

The STRIDE trial demonstrates that once-weekly semaglutide significantly enhances walking capacity in patients with symptomatic peripheral artery disease and type 2 diabetes, irrespective of baseline diabetes duration, BMI, HbA1c levels, or diabetes medication use.

Cardiology Specialties

Lipoprotein(a) as a Prognostic Indicator for Extracoronary Atherosclerotic Disease Progression: Insights from the UK Biobank

By MedXY 09/06/2025

Elevated lipoprotein(a) levels significantly predict incident peripheral artery disease and carotid stenosis, as well as progression to major limb events, underscoring its value as a prognostic biomarker for extracoronary atherosclerotic vascular complications.

Cardiology Family Medicine & Nutrition news Specialties

Early Warnings of Vascular Blockage: Don’t Ignore These 4 Signs in Your Hands and Feet

By MedXY 08/23/2025

Discover the crucial early signs of vascular blockage in hands and feet, simple self-check methods, and expert insights to protect your circulatory health effectively.

Cardiology Clinical Updates Medical News Neurology Specialties

Lipoprotein(a) as an Independent Predictor of Peripheral Artery Disease and Carotid Stenosis: Insights from a Large UK Biobank Study

By MedXY 08/01/2025

A landmark UK Biobank study demonstrates that elevated lipoprotein(a) independently predicts both the onset and progression of peripheral artery disease and carotid stenosis, beyond traditional cardiovascular risk factors.